已核实 DOI PubMed 相关产品: 0

Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors

Journal 2022 · IF 7.088 · 发表于 2022 年 3 月 2 日
作者: Qidong Tang,Ting Peng,Jie Hu,Tao Zhang,Pengqin Chen,Daoxing Chen,Yunjie Wang,Lingfeng Chen,Linjiang Tong,Yi Chen,Hua Xie,Guang Liang
阅读全文 在 PubMed 查看

摘要

Pan-HER inhibitors exhibit extensive biological activity and offer unique advantages and usually bind to targets in an irreversible manner. Owing to the off-target toxicity of irreversible inhibitors, reversible pan-HER inhibitors are desirable. Herein, we describe the process of N -(ring structure fused phenyl)quinazoline-4-amine-based design, synthesis, and biological evaluation of pan-HER inhibitors in vitro and in vivo . Compound C5 , with the molecular skeleton of N -(3-bromo-1 H -indol-5-yl)-quinazolin-4-amine, displayed irreversible binding just like other effective pan-HER inhibitors. To our surprise, compound C6, which possessed the same skeleton, was found to be a high-strength reversible pan-HER inhibitor. This compound was capable of inhibiting HER1s (such as EGFR T790M/L858R and WT), HER2, and HER4 and can be considered as a breakthrough in the development of pan-HER inhibitors. Altogether, N -(3-bromo-1 H -indol-5-yl)-quinazolin-4-amine can serve as an effective molecular skeleton for developing both reversible and irreversible pan-HER inhibitors in the following discovery of antitumor drugs .